Phase I Study of P-cadherin-targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors.
Vivek SubbiahWilliam ErwinOsama MawlawiAsa McCoyDavid WagesCatherine WheelerCarlos Gonzalez-LeperaHolly LiuHomer MacapinlacFunda Meric-BernstamDavid S HongShubham PantDao LeElmer SantosJose GonzalezJason RoszikTakeaki SuzukiRuth Ann SubachTimothy MaddenMary J JohansenFumiko NomuraHirokazu SatohTadashi MatsuuraMasamichi KajitaEri NakamuraYuichi FunaseSatoshi MatsushimaGregory RavizziniPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
The favorable safety profile and initial antitumor activity observed for 90Y-FF-21101 warrant further evaluation of this radioimmunotherapeutic (RIT) approach and provide initial clinical data supporting P-cadherin as a potential target for cancer treatment.